Yahoo
NasdaqGM - Nasdaq Real Time Price USD

ADMA Biologics, Inc. (ADMA)

11.41 -0.34 (-2.89%)
At close: October 30 at 4:00:00 PM EDT
11.25 -0.16 (-1.40%)
After hours: October 30 at 6:21:40 PM EDT
Trade ADMA on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Adam S. Grossman
Co-Founder, President, CEO & Director 2.14M 1.95M 1977
Dr. Jerrold B. Grossman D.P.S., Ph.D.
Co-Founder & Vice Chairman of the Board 90k -- 1948
Mr. P. Terence Kohler
CFO & Treasurer 46.97k -- --
Ms. Kaitlin M. Kestenberg
COO & Senior VP of Compliance 988.66k 50.5k 1987
Mr. Michael Goldstein
General Counsel -- -- --
Mr. John Hafl
Executive Director of Sales -- -- --
Mr. Skyler Bloom
Senior Director of Business Development & Corporate Strategy -- -- --

ADMA Biologics, Inc.

465 State Route 17
Ramsey, NJ 07446
United States
201 478 5552 https://www.admabiologics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
640

Description

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Corporate Governance

ADMA Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 4, 2026 at 9:00 PM UTC

ADMA Biologics, Inc. Earnings Date

Recent Events

August 5, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 2, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 6, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 4, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 15, 2026 at 12:00 AM UTC

DEFA14A: Proxy Statements

March 27, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 2, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 25, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 5, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: